Secondary osteoporosis in patients with rheumatoid arthritis, prevention of complications with Osteomed, Osteomed Forte, Osteo-Vit D3

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Rheumatoid arthritis is one of the most common autoimmune systemic connective tissue diseases of unknown etiology. Prescribing glucocorticosteroids to patients is associated with loss of bone mass and an increased risk of osteoporosis and osteoporotic fractures. The issues of medical and social significance, clinical and pathogenetic aspects of the development and progression of secondary osteoporosis in rheumatoid arthritis patients need further discussion. Objective. To study medical and social significance, clinical and pathogenetic aspects of secondary osteoporosis in patients with rheumatoid arthritis, questions of complications prevention, including Osteomed, Osteomed Forte, Osteo-Vit D3 prescription. Material and methods. Analysis of 17 Russian and 26 foreign publications, devoted to the problem of the secondary osteoporosis in patients with rheumatoid arthritis, complex prevention of complications, osteoporosis fractures, including Osteomed, Osteomed Forte, Osteo-Bit D3 prescription. Results. It was shown that patients with secondary osteoporosis and rheumatoid arthritis taking Osteomed, Osteomed Forte, Osteo Vit D3 as opposed to patients who didn't get the mentioned preparations had a decreased intensity of pain syndrome, a rate of bone tissue resorption, increased serum calcium concentration, mineral density of bone tissue, improved scores of quality of life. Conclusion. Prescription of Osteomed, Osteomed Forte, Osteo Vit D3 can be recommended in real clinical practice in patients with secondary osteoporosis and rheumatoid arthritis with the account of the personalized approach while choosing the treatment tactics.

Full Text

Restricted Access

About the authors

Dmitry Vasilievich Dedov

Tver State Medical University of the Ministry of Health of the Russian Federation; Regional Clinical Cardiological Dispensary

Author for correspondence.
Email: dedov_d@inbox.ru
MD, PhD, associate professor, professor of the department; cardiologist

References

  1. Делягин В. Остеопения и остеопороз и их терапия в амбулаторных условиях. Врач. 2015; 11: 31-6.
  2. Остроумова О.Д., Голобородова И.В. Лекарственно-индуцированный остеопороз. Клиническая фармакология и терапия. 2020; 29 (3): 73-9. doi: 10.32756/0869- 5490-2020-3-73-79
  3. Cosman F., de Beur S.J., LeBoff M.S. et al. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25 (10): 2359-81. doi: 10.1007/s00198-014-2794-2
  4. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я. и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы эндокринологии. 2017; 63 (6): 392-426. doi: 10.14341/probl2017636392-426
  5. Струков В., Кислов А., Елистратов Д. и др. Персонифицированный подход в терапии остеопороза у пожилых. Врач. 2015; 6: 51-3.
  6. Яриков А.В., Денисов А.А., Масевнин С.В. и др. Остеопороз в практике вертебролога. Врач. 2020; 3: 11-8. [Yarikov A.V., Denisov A.A., Masevnin S.V. i dr. Osteoporosis in the practice of a vertebrologist. Vrach. 2020; 3: 11-8 (in Russian)]. https://doi.org/10.29296/25877305-2020-03-02
  7. Compston J.E., McClung M.R., Leslie W.D. Osteoporosis. Lancet. 2019; 393 (10169): 364-76. doi: 10.1016/S0140-6736(18)32112-3.
  8. Павлова Т., Башук И. Клинико-морфологические особенности дегенеративных изменений костной ткани на фоне остеопороза в возрастном аспекте. Врач. 2019; 6: 47-50. [Pavlova T., Bashuk I. Clinical and morphological features of degenerative changes in bone tissue against osteoporosis in the age aspect. Vrach. 2019; 6: 47-50 (in Russian)]. https://doi.org/10.29296/25877305-2019-06-11
  9. Юрова О., Марченкова Л. Опыт применения БАД Остеомед Форте в комплексной программе реабилитации пациентов с переломом дистального отдела предплечья на фоне системного остеопороза. Врач. 2020; 2: 47-52. [Yurova O., Marchenkova L. Experience of Osteomed Forte in a complex program of rehabilitation of patients with distal forearm fracture against the background of systemic osteoporosis. Vrach. 2020; 2: 47-52 (in Russian)]. https://doi.org/10.29296/25877305-2020-02-11
  10. Lems W.F., Dreinho fer K.E., Bischoff-Ferrari H. et al. EULAR/ EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. Ann Rheum Dis. 2017; 76 (5): 802-10. https://doi.org/10.1136/annrheum-dis-2016-210289.
  11. Pierini F.S., Brom M., Scolnik M. at al. Osteoporotic fractures in rheumatoid arthritis patients in Argentina: a matched retrospective cohort study. Adv Rheumatol. 2021; 61 (1): 21. doi: 10.1186/s42358-021-00179-3
  12. Барилко М., Цурцумия Д., Селиверстов П. и др. Остеомед в практике врача-терапевта. Врач. 2017; 3: 37-40.
  13. Пешехонова Л.К., Пешехонов Д.В., Красюков П.А. Клиническая эффективность применения препаратов Остеомед, Остеомед Форте, Остео-Вит D3 у больных вторичным остеопорозом при ревматоидном артрите. Врач. 2020; 4: 68-74. [Peshexonova L.K., Peshexonov D.V., Krasyukov P.A. Clinical efficacy of Osteomed, Osteomed Forte, Osteo-Vit D3 in patients with secondary osteoporosis in rheumatoid arthritis. Vrach. 2020; 4: 68-74 (in Russian)]. https://doi.org/10.29296/25877305-2020-04-12
  14. Maricic M. Update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2011; 37 (3): 415-31. DOI: 10.1016/j. rdc.2011.07.003
  15. Duru N., van der Goes M.C., Jacobs J.W. et al. EULAR evidence-based and consensusbased recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013; 72 (12): 1905-13. https://doi.org/10.1136/annrheum-dis-2013-203249
  16. Buttgereit F. SP0160 2018 EULAR recommendations for the use of glucocorticoid therapy. Ann Rheum Dis. 2018; 77 (2): 42.
  17. Струков В., Елистратов Д., Кислов А. и др. Остеопороз в гериатрической практике. Врач. 2018; 6: 26-30. [Strukov V., Elistratov D., Kislov A. i dr. Osteoporosis in Geriatric Practice. Vrach. 2018; 6: 26-30 (in Russian)]. https://doi.org/10.29296/25877305-2018-06-05
  18. Прохоров М., Кислов А., Елистратов Д. и др. Влияние Остеомеда на консолидацию переломов костей. Врач. 2016; 2: 68-9.
  19. Dimitroulas T., Nikas S.N., Trontzas P. et al. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev. 2013; 12 (10): 958-66. doi: 10.1016/j.autrev.2013.03.015.
  20. Adler R.A. Laboratory testing for secondary osteoporosis evaluation. Clin Biochem. 2012; 45 (12): 894-900. doi: 10.1016/j.clinbio-chem.2012.01.024.
  21. Джоунс О., Струков В., Кислов А. и др. Коморбидный остеопороз: проблемы и новые возможности диагностики (ч. 1). Врач. 2017; 10: 23-7.
  22. Джоунс О., Струков В., Кислов А. и др. Коморбидный остеопороз: проблемы и новые возможности терапии (ч. 2). Врач. 2017; 11: 25-9.
  23. Трифонов В., Елистратов Д. Рекомендации по лечению остеопороза в условиях коморбидности и полипрагмазии с помощью препарата «Остеомед форте» и фитопрепаратов. Врач. 2018; 5: 87-8.
  24. Smolen J.S., Collaud Basset S., Boers M. et al.; European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Ann Rheum Dis. 2016; 75 (7): 1268-71. doi: 10.1136/annrheumdis-2016-209429.
  25. Adami G., Fassio A., Rossini M. et al. Osteoporosis in Rheumatic Diseases. Int J. Mol Sci. 2019; 20 (23): 5867. DOI: 10.3390/ ijms20235867.
  26. Briot K. Bone and glucocorticoids. Ann Endocrinol (Paris). 2018; 79 (3): 115-8. doi: 10.1016/j.ando.2018.04.016
  27. Dimitroulas T., Nikas S.N., Trontzas P. et al. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev. 2013; 12 (10): 958-66. doi: 10.1016/j.autrev.2013.03.015.
  28. Okano T., Inui K., Tada M. et al. High frequency of vertebral fracture and low bone quality in patients with rheumatoid arthritis-Results from TOMORROW study. Mod Rheumatol. 2017; 27 (3): 398404. doi: 10.1080/14397595.2016.1213943.
  29. Jin S., Hsieh E., Peng L. et al. Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int. 2018; 29 (6): 1263-75. doi: 10.1007/s00198-018-4473-1.
  30. Бестаев Д., Божьева Л., Насонов Е. Интерстициальное поражение легких при ревматоидном артрите (показатели ФВД и КТ высокого разрешения). Врач. 2015; 2: 43-5.
  31. Кавалерский Г., Грицюк А., Сметанин С. Артропластика коленного сустава при ревматоидном артрите. Врач. 2016; 12: 44-7.
  32. Chen J., Liu W., Lin Q. et al. Vitamin D. deficiency and low bone mineral density in native Chinese rheumatoid arthritis patients. Int J. Rheum Dis. 2014; 17 (1): 66-70. doi: 10.1111/1756-185X.12160.
  33. Mullen M.B., Saag K.G. Evaluating and mitigating fracture risk in established rheumatoid arthritis. Best Pract Res Clin. Rheumatol. 2015; 29 (4-5): 614-27. doi: 10.1016/j.berh.2015.09.005
  34. Wysham K.D., Shoback D.M., Andrews J.S. et al. Sex differences in frailty and its association with low bone mineral density in rheumatoid arthritis. Bone Rep. 2020; 12: 100284. doi: 10.1016/j.bonr.2020.100284.
  35. Buckley L, Guyatt G., Fink H.A. et al. American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017; 69 (8): 1521-37. doi: 10.1002/art.40137.
  36. Hoes J.N., Bultink I.E., Lems W.F. Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother. 2015; 16 (4): 559-71. doi: 10.1517/14656566.2015.997709.
  37. Raterman H.G., Bultink I.E., Lems W.F. Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention. Expert Opin Pharmacother. 2020; 21 (14): 1725-37. doi: 10.1080/14656566.2020.1787381.
  38. Degli Esposti L., Girardi A., Saragoni S. et al. Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk. Endocrine. 2019; 64 (2): 367-77. doi: 10.1007/s12020-018-1824-9.
  39. Vojinovic J., Tincani A., Sulli A. et al. European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO). Autoimmun Rev. 2017; 16 (5): 548-54. DOI: 10.1016/j. autrev.2017.03.002.
  40. Бекетова Т.В. Обзор рекомендаций Европейской антиревматической лиги (EULAR), рассмотренных в 2018 г. Современная ревматология. 2019; 13 (2): 22-4. [Beketova T.V. A review of the European League Against Rheumatism (EULAR) recommendations reviewed in 2018. Sovremennaya revmatologiya. 2019; 13 (2): 22-4 (in Russian)]. https://doi.org/10.14412/1996-7012-2019-2-22-24
  41. Roth D.E., Abrams S.A., Aloia J. et al. Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low- and middle-income countries. Ann N Y Acad Sci. 2018; 1430 (1): 44-79. doi: 10.1111/nyas.13968.
  42. Nemeth E.F., Shoback D. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders. Best Pract Res Clin Endocrinol Metab. 2013; 27 (3): 373-84. doi: 10.1016/j.beem.2013.02.008.
  43. Goldring SR. Inflammatory signaling induced bone loss. Bone. 2015; 80: 143-9. doi: 10.1016/j.bone.2015.05.024.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies